IOWA | Health and Human Services

PRIORIX (MMR) Vaccine Summary

April 2025

Food and Drug Administration (FDA)

June 6, 2022, the FDA licensed PRIORIX (MMR) for use in individuals aged 12 months and older.

Advisory Committee on Immunization Practices (ACIP)

Measles, Mumps, Rubella Vaccine (PRIORIX): Recommendations of the Advisory Committee on Immunization Practices — United States, 2022

ACIP Recommended Schedule for MMR Vaccine

Priorix is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella.

Anyone born after 1957 should be able to produce documentation of two doses of a live-attenuated measles vaccine. **Anyone without documentation of a measles vaccine who is in doubt about their vaccine status should receive at least one dose of MMR.**

Healthcare personnel, international travelers, and students at post-high school educational institutions should receive two doses of MMR, separated by at least 28 days (https://www.cdc.gov/vaccines/vpd/mmr/public/index.html).

Interchangeability

PRIORIX and M-M-R II are fully interchangeable. ACIP General Best Practices for Immunization states a preference that doses of vaccine in a series come from the same manufacturer; however, vaccination should not be deferred when the manufacturer of the previously administered vaccine is unknown or when the vaccine from the same manufacturer is unavailable.

Timing of Vaccination and Coadministration with Other Vaccines

PRIORIX can be administered concomitantly, at different anatomic sites, with other routine vaccines. Live virus vaccines not given on the same day should be separated by ≥ 4 weeks.

Recommended Dosage and Administration

The recommended dose of Priorix is 0.5mL administered as a subcutaneous injection.

How Supplied

PRIORIX is a suspension for injection supplied as a single dose vial of lyophilized antigen component to be reconstituted with the accompanying prefilled syringe of sterile water diluent component. The reconstituted vaccine should be a clear peach to fuchsia pink colored suspension. Administer immediately after reconstitution. If not used immediately, store refrigerated between 36° and 46° F (2° and 8°C) and administer within 8 hours. Discard reconstituted vaccine if not used within 8 hours.

Vaccine Storage and Handling

PRIORIX cannot be stored in the freezer. Vials of the lyophilized antigen component must be stored refrigerated between 36° and 46° F (2° and 8°C). Protect vials from light. Prefilled ungraduated syringes of sterile water diluent should be stored refrigerated between 36°F and 46°F (2 °C and 8°C) or at controlled room temperature up to 77°F (25°C). Do not freeze lyophilized antigen component or sterile water diluent.

Precautions

- Moderate or severe acute illness with or without fever
- Recent (within 11 months) receipt of antibody-containing blood products. Specific interval depends on product type. See www.cdc.gov/vaccines/hcp/imz-best-practices/timing-spacing-immunobiologics.html, Table 3-6, for more information.
- History of thrombocytopenia or thrombocytopenic purpura
- Need for tuberculin skin testing or interferon gamma release assay (IGRA) testing

Contraindications

- History of a severe allergic reaction (anaphylaxis) to any component of the vaccine or following a previous dose of any measles, mumps, and rubella virus containing vaccine (PRIORIX does not contain gelatin)
- Pregnancy (pregnancy should also be avoided for 1 month after receipt of MMR vaccine)
- Severe immunosuppression from either disease or therapy
- Family history of altered immunocompetence, unless verified clinically or by laboratory testing as immunocompetent
- Always consult the package insert for precautions, warning and contraindications and the most current guidance from CDC.

Reporting of Adverse Events

Adverse events following administration of any vaccine should be reported to the Vaccine Adverse Event Reporting System (VAERS). Reports can be submitted to VAERS online, by fax, or by mail. Additional information about VAERS is available by telephone (1-800-822-7967) or online (https://vaers.hhs.gov).